Glaukos (NYSE:GKOS) Announces Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Glaukos (NYSE:GKOS) released its quarterly earnings results on Wednesday. The medical instruments supplier reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.12, FiscalAI reports. The company had revenue of $150.57 million for the quarter, compared to analyst estimates of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.78%. The firm’s revenue was up 41.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.22) earnings per share.

Here are the key takeaways from Glaukos’ conference call:

• Record Q1 net sales of $150.6 million, up 41% year-over-year, and management raised full‑year 2026 net sales guidance to $620–$635 million from $600–$620 million.
• iDose TR momentum drove U.S. glaucoma net sales to a record $93.5 million (up 58%), with iDose TR contributing approximately $54 million and management citing growing surgeon adoption and reimbursement progress.
• Clinical and regulatory progress for interventional glaucoma: two phase IV studies are enrolling (including iDose+ cataract vs cataract alone), re‑administration procedures are occurring, and the company plans to file for iDose TR by year‑end aiming for targeted approval in Q4 2027.
• Epioxa commercial launch is underway with U.S. availability, a permanent CMS J‑code (J2789) effective July 1, 2026, payer pathways covering >100 million commercial lives (including four of five largest payers), and a site‑of‑care network already reaching ~65% of the U.S. population with plans toward ~95%.
• Near‑term headwinds: measured adoption and volatility are expected as Epioxa transitions from Photrexa and operates under a miscellaneous J‑code until July, international growth may see comp‑competitive trialing and FX tailwinds are expected to abate, and management expects possible Q2 corneal sales softness during the transition.

Glaukos Price Performance

Shares of GKOS traded down $2.40 during trading hours on Friday, hitting $141.27. 602,207 shares of the stock were exchanged, compared to its average volume of 778,996. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69. Glaukos has a 12-month low of $73.16 and a 12-month high of $146.75. The company has a market cap of $8.27 billion, a price-to-earnings ratio of -43.09 and a beta of 0.78. The stock’s 50-day moving average price is $114.02 and its two-hundred day moving average price is $107.68.

Wall Street Analysts Forecast Growth

GKOS has been the topic of several analyst reports. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. The Goldman Sachs Group restated a “buy” rating and set a $138.00 price target on shares of Glaukos in a research report on Friday, January 9th. BTIG Research raised their price target on shares of Glaukos from $131.00 to $141.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research report on Tuesday, April 21st. Finally, Piper Sandler restated an “overweight” rating and set a $165.00 price target on shares of Glaukos in a research report on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $138.85.

Insider Activity at Glaukos

In related news, Director Aimee S. Weisner sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $117.38, for a total transaction of $1,760,700.00. Following the completion of the sale, the director directly owned 18,806 shares in the company, valued at approximately $2,207,448.28. The trade was a 44.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Alex R. Thurman sold 2,511 shares of the business’s stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $106.46, for a total value of $267,321.06. Following the sale, the chief financial officer owned 41,967 shares of the company’s stock, valued at $4,467,806.82. The trade was a 5.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 19,657 shares of company stock valued at $2,250,060 over the last quarter. 5.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Glaukos

Hedge funds and other institutional investors have recently modified their holdings of the business. Empowered Funds LLC purchased a new position in shares of Glaukos in the fourth quarter worth about $217,000. Guggenheim Capital LLC acquired a new stake in shares of Glaukos in the fourth quarter valued at approximately $233,000. MML Investors Services LLC acquired a new stake in shares of Glaukos in the fourth quarter valued at approximately $208,000. First Trust Advisors LP acquired a new stake in shares of Glaukos in the fourth quarter valued at approximately $221,000. Finally, State of Wyoming increased its holdings in shares of Glaukos by 16.3% in the fourth quarter. State of Wyoming now owns 2,003 shares of the medical instruments supplier’s stock valued at $226,000 after purchasing an additional 280 shares during the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Q1 results beat and raised guidance — Glaukos reported record net sales of $150.6M (up ~41% YoY) and EPS of ($0.18) that topped estimates; management raised FY‑2026 revenue guidance to $620M–$635M, above consensus. This is the primary catalyst lifting the stock. Glaukos Announces First Quarter 2026 Financial Results
• Positive Sentiment: After‑hours reaction and analyst attention — The strong quarter produced a notable after‑hours pop and widespread coverage of the earnings call and transcripts, amplifying short‑term momentum. Glaukos Up 10% After-Hours After Q1 Earnings Beat
• Positive Sentiment: Wells Fargo raised its price target to $138 and kept an overweight rating, signaling institutional confidence in growth drivers. Glaukos (NYSE:GKOS) Given New $138.00 Price Target at Wells Fargo & Company
• Positive Sentiment: BTIG lifted its target to $141 and reiterated a buy rating, another bullish signal from the sell side. Glaukos (NYSE:GKOS) Given New $141.00 Price Target at BTIG Research
• Positive Sentiment: Needham issued a positive forecast and raised its target (to $136), reflecting constructive views on the company’s glaucoma and corneal momentum. Needham & Company LLC Issues Positive Forecast for Glaukos (NYSE:GKOS) Stock Price
• Neutral Sentiment: JPMorgan raised its target to $140 with an overweight rating, but the updated targets from brokers still sit near or slightly below the current market price — suggesting upside expectations are being tightened to reflect valuation. JPMorgan Chase & Co. Price Target Note
• Negative Sentiment: Profitability remains a watch item — Glaukos is still operating at a loss (negative net margin and negative ROE), so continued top‑line execution must translate into durable profit improvement for long‑term re-rating. Glaukos Q1 Earnings Summary

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.